Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Meignan

Showing results (111-120 of 125) with videos related to

Pageof 13
Sort By:
Haematologica|March 25, 2014
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scaleAndrea Gallamini, Sally F Barrington, Alberto Biggi, et al.
Blood Advances|November 12, 2020
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphomaLaetitia Vercellino, Roberta Di Blasi, Salim Kanoun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2021
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell LymphomaStefan Alig, Charles W Macaulay, David M Kurtz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 TrialMarc P E André, Théodore Girinsky, Massimo Federico, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline <sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical ImplementationRonald Boellaard, Irène Buvat, Christophe Nioche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II TrialLuc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)Emmanuel Bachy, Vincent Camus, Catherine Thieblemont, et al.
Blood|January 25, 2020
High total metabolic tumor volume at baseline predicts survival independent of response to therapyLaetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, et al.
Blood Advances|January 26, 2021
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphomaFrançois Lemonnier, Violaine Safar, Asma Beldi-Ferchiou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2019
Reply to J. Wang et alDavid M Kurtz, Florian Scherer, Michael C Jin, et al.
Pageof 13

Showing results (111-120 of 125) with videos related to

Sort By:
Pageof 13
Haematologica|March 25, 2014
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scaleAndrea Gallamini, Sally F Barrington, Alberto Biggi, et al.
Blood Advances|November 12, 2020
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphomaLaetitia Vercellino, Roberta Di Blasi, Salim Kanoun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2021
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell LymphomaStefan Alig, Charles W Macaulay, David M Kurtz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 TrialMarc P E André, Théodore Girinsky, Massimo Federico, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline <sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical ImplementationRonald Boellaard, Irène Buvat, Christophe Nioche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II TrialLuc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)Emmanuel Bachy, Vincent Camus, Catherine Thieblemont, et al.
Blood|January 25, 2020
High total metabolic tumor volume at baseline predicts survival independent of response to therapyLaetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, et al.
Blood Advances|January 26, 2021
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphomaFrançois Lemonnier, Violaine Safar, Asma Beldi-Ferchiou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2019
Reply to J. Wang et alDavid M Kurtz, Florian Scherer, Michael C Jin, et al.
Pageof 13